Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204.SZ) SHZ
Currency In CNY
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In CNY
Address
No. 36, Jinghai Er Road
Beijing, 100176
China
Phone
86 10 6751 9888
Website
Sector
Healthcare
Industry
Biotechnology
Employees
555
First IPO Date
April 15, 2011
| Name | Title | Pay | Year Born |
| Shicheng Li | Head of Accounting & Financial Director | 0 | 1982 |
| Maorong Yu | Secretary of the Board & Deputy GM | 0 | 1981 |
| Wang Chao | General Manager | 0 | 1982 |
Staidson (Beijing) BioPharmaceuticals Co., Ltd. is a Chinese biopharmaceutical company that specializes in the entire lifecycle of therapeutic drugs, from research and development to production and market distribution. Their product portfolio encompasses a variety of drug types, including advanced protein-based medicines like therapeutic monoclonal antibodies, innovative gene and cell therapies, and conventional chemical pharmaceuticals. The company's primary therapeutic areas address conditions related to the nervous system, infectious diseases, gastrointestinal health, the urinary system, and autoimmune disorders. Notably, Staidson has established a strategic partnership with Pivotal S.L. to conduct clinical trials in Europe for BDB-001, a monoclonal anti-C5a antibody, aimed at treating patients with severe, progressive COVID-19 caused by the SARS-CoV-2 virus. Founded in 2002, the company's headquarters are located in Beijing, China.